Payment overview · 2025
General Payments
$722.05
38 reported records · 16 companies
Healthcare provider profile · identity verified
Paul A Schmidt, MD
Allopathic & Osteopathic Physicians|Family Medicine · GLEN ROSE, TX · NPI 1073516704
Verified facts
What the public records show
CMS Open Payments records show Paul A Schmidt, MD received $722.05 in general payments during 2025 across 38 reported records.
Supernus Pharmaceuticals, Inc. accounted for 12.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 203 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $86.36 | 12.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $83.91 | 11.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.47 | 11.4% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.68 | 9.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $66.62 | 9.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $58.48 | 8.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.09 | 7.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.31 | 6.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.42 | 4.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.56 | 4.7% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.06 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.79 | 3.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.51 | 3.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.75 | 2.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.15 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $722.05 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $86.36 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.91 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $82.47 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $67.68 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $66.62 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.31 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.15 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
203 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1040 | 290 |
| Atorvastatin Calcium | Atorvastatin Calcium | 718 | 190 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 661 | 114 |
| Alprazolam | Alprazolam | 422 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 380 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 92 |
| Lisinopril | Lisinopril | 352 | 106 |
| Tamsulosin Hcl | Tamsulosin Hcl | 304 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 92 |
| Gabapentin | Gabapentin | 292 | 77 |
| Montelukast Sodium | Montelukast Sodium | 258 | 79 |
| Metformin Hcl | Metformin Hcl | 250 | 65 |
| Finasteride | Finasteride | 247 | 70 |
| Furosemide | Furosemide | 242 | 68 |
| Losartan Potassium | Losartan Potassium | 237 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 67 |
| Tramadol Hcl | Tramadol Hcl | 229 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 227 | 73 |
| Mounjaro | Tirzepatide | 222 | 41 |
| Omeprazole | Omeprazole | 205 | 53 |
| Eliquis | Apixaban | 203 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 200 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 187 | 75 |
| Ezetimibe | Ezetimibe | 184 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 44 |
| Bupropion Xl | Bupropion Hcl | 176 | 43 |
| Jardiance | Empagliflozin | 169 | 30 |
| Trazodone Hcl | Trazodone Hcl | 169 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 164 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 49 |
| Meloxicam | Meloxicam | 142 | 32 |
| Spironolactone | Spironolactone | 138 | 37 |
| Carvedilol | Carvedilol | 132 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 117 | 31 |
| Allopurinol | Allopurinol | 115 | 30 |
| Temazepam | Temazepam | 115 | 22 |
| Xarelto | Rivaroxaban | 111 | 19 |
| Glipizide | Glipizide | 110 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 27 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 104 | 21 |
| Potassium Chloride | Potassium Chloride | 104 | 27 |
| Pregabalin | Pregabalin | 104 | 27 |
| Fluconazole | Fluconazole | 102 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 99 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 24 |
| Estradiol | Estradiol | 94 | 29 |
| Clonazepam | Clonazepam | 88 | 16 |
| Synthroid | Levothyroxine Sodium | 85 | 24 |
| Ozempic | Semaglutide | 83 | 18 |
| Sertraline Hcl | Sertraline Hcl | 83 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 13 |
| Famotidine | Famotidine | 72 | 21 |
| Simvastatin | Simvastatin | 68 | 20 |
| Alendronate Sodium | Alendronate Sodium | 67 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 64 | 43 |
| Trulicity | Dulaglutide | 64 | suppressed |
| Methocarbamol | Methocarbamol | 61 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 58 | 19 |
| Liothyronine Sodium | Liothyronine Sodium | 58 | 23 |
| Lorazepam | Lorazepam | 58 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | 12 |
| Armour Thyroid | Thyroid,pork | 55 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 49 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 36 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Azelastine Hcl | Azelastine Hcl | 50 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | suppressed |
| Prednisone | Prednisone | 47 | 22 |
| Valacyclovir | Valacyclovir Hcl | 47 | 11 |
| Atenolol | Atenolol | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 12 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Primidone | Primidone | 45 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 25 |
| Celecoxib | Celecoxib | 42 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Anastrozole | Anastrozole | 39 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 15 |
| Ibuprofen | Ibuprofen | 36 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | 12 |
| Np Thyroid | Thyroid,pork | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 16 |
| Naproxen | Naproxen | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 25 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 17 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 13 |
| Diazepam | Diazepam | 15 | suppressed |
| Famciclovir | Famciclovir | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Niva Thyroid | Thyroid,pork | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Xopenex Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Clomid | Clomiphene Citrate | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $722.05 · 38 records | Supernus Pharmaceuticals, Inc. | AIRSUPRA, Auvelity, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE, GARDASIL 9, IBSRELA, Kerendia, M-M-R II, NURTEC ODT, OTEZLA, Ozempic, Qelbree, REPATHA, REXULTI, The Cologuard Plus Collection Kit, VAXNEUVANCE, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error